ArticleInfection and immunity1998
A vaccine and monoclonal antibodies that enhance mouse resistance to Candida albicans vaginal infection.
Article in Infection and immunity, 1998. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 56 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
56 citing papers in PubMed, 172 citations in OpenAlex.
- Monoclonal antibodies: From magic bullet to precision weapon.Molecular biomedicine · 2024Review
- Antibodies to Combat Fungal Infections: Development Strategies and Progress.Microorganisms · 2023Review
- Article
- Vaccines against candidiasis: Status, challenges and emerging opportunity.Frontiers in cellular and infection microbiology · 2022Review
- The Role of B-Cells and Antibodies againstVaccines · 2021Review
- Monoclonal Antibodies as Tools to Combat Fungal Infections.Journal of fungi (Basel, Switzerland) · 2020Review
- Therapies and Vaccines Based on Nanoparticles for the Treatment of Systemic Fungal Infections.Frontiers in cellular and infection microbiology · 2020Review
- Design of a mimotope-peptide based double epitope vaccine against disseminated candidiasis.Vaccine · 2019Article
- NMR comparison of hyphal and yeast Candida albicans serotype B mannans.European biophysics journal : EBJ · 2018Article
- Liposomal vaccine formulations as prophylactic agents: design considerations for modern vaccines.Journal of nanobiotechnology · 2017Review
- β-1,2-Mannosyltransferases 1 and 3 Participate in Yeast and Hyphae O- and N-Linked Mannosylation and Alter Candida albicans Fitness During Infection.Open forum infectious diseases · 2015Article
- The protective role of immunoglobulins in fungal infections and inflammation.Seminars in immunopathology · 2015Review
- Adaptive immune responses to Candida albicans infection.Virulence · 2015Review
- Emerging drugs and vaccines for candidemia.Mycoses · 2014Review
- NDV-3 protects mice from vulvovaginal candidiasis through T- and B-cell immune response.Vaccine · 2013Article
- Molecular recognition of Candida albicans (1->2)-β-mannan oligosaccharides by a protective monoclonal antibody reveals the immunodominance of internal saccharide residues.The Journal of biological chemistry · 2012Article
- Cytokines in the host response to Candida vaginitis: Identifying a role for non-classical immune mediators, S100 alarmins.Cytokine · 2012Review
- Murine model of dextran sulfate sodium-induced colitis reveals Candida glabrata virulence and contribution of β-mannosyltransferases.The Journal of biological chemistry · 2012Article
- Article
- Immunochemistry of pathogenic yeast, Candida species, focusing on mannan.Proceedings of the Japan Academy. Series B, Physical and biological sciences · 2012Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
We previously reported that a vaccine composed of liposome-mannan complexes of Candida albicans (L-mann) stimulates mice to produce protective antibodies against disseminated candidiasis. An immunoglobulin M (IgM) monoclonal antibody (MAb), B6.1, specific for a beta-1,2-mannotriose in the complexes protects against the disease, whereas MAb B6 does not. In the present study, the vaccine and MAbs B6.1 and B6 were tested for the ability to protect against Candida vaginal infection, established by intravaginal (i.vg.) inoculation of yeast cells in mice maintained in pseudoestrus. Fungal CFU in each vagina was determined to assess the severity of infection. Mice vaccinated before infection developed about 62% fewer vaginal CFU than nonimmunized controls. Naive mice that received polyclonal antiserum (from vaccinated mice) i.vg. before infection had 60% fewer CFU than controls. The serum protective factor was stable at 56 degreesC, but C. albicans cells absorbed this factor. Mice given MAb B6.1 i.vg. after infection was established had fewer Candida CFU in vaginal tissue than control mice given buffer instead of antibody. MAbs B6.1 and B6 given intraperitoneally before infection protected mice, but MAbs preabsorbed with yeast cells did not. MAb B6.1 also protected against C. tropicalis vaginal infection, but MAb B6 did not. The protective activities of MAbs B6.1 and B6 appeared to be specific because an irrelevant IgM carbohydrate-specific MAb and an irrelevant IgG protein-specific MAb were not protective; also, MAb B6.1 did not affect development of vaginal chlamydial infection. These studies show that an appropriate antibody response, or administration of protective antibodies, can help the host to resist Candida vaginal infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.